Sudarshan Pharma Industries Ltd. exhibits moderate growth and profitability metrics compared to its peers in the pharmaceuticals sector. While its revenue growth and profitability margins are lower than the sector leaders, its valuation metrics suggest it may be undervalued relative to its earnings potential, making it a potential candidate for investors looking for growth opportunities.

• • Sudarshan Pharma's revenue growth is 8.95% YoY, lower than industry leaders like Mankind Pharma with 18.12%.
• • It has a PE ratio of 49.67 which is higher than some peers indicating a potentially high valuation.
• • ROE at 10.77% is below the average in the sector, indicating room for improvement in profitability.
• • The debt-equity ratio of 0.94 suggests moderate leverage compared to peers.
• • Overall, Sudarshan Pharma is positioned as a growth opportunity but may have to improve operational efficiency.